Authors

• Kazuto Nishio (ORCID: https://orcid.org/0000-0002-8275-0846)
• Kiyotaka Yoh
• Kazuo Kasahara (ORCID: https://orcid.org/0000-0001-5551-1543)
• S. Varughese (ORCID: https://orcid.org/0000-0002-0851-5709)
• Sotaro Enatsu
• Kazumi Nishino (ORCID: https://orcid.org/0000-0003-2000-7472)
• Miyako Satouchi (ORCID: https://orcid.org/0000-0003-0613-9487)
• Hidetoshi Hayashi (ORCID: https://orcid.org/0000-0001-8787-5587)
• Carla Visseren‐Grul (ORCID: https://orcid.org/0000-0003-2010-1514)
• Tomoko Matsui (ORCID: https://orcid.org/0000-0001-9525-0018)
• Makoto Nishio (ORCID: https://orcid.org/0000-0003-4969-4165)
• Kazuhiko Nakagawa
• Takashi Seto

Institutions

• National Hospital Organization Kyushu Cancer Center (JP)
• Eli Lilly (Japan) (JP)
• Eli Lilly (India) (IN)
• Eli Lilly (Netherlands) (NL)
• The Cancer Institute Hospital (JP)
• National Cancer Center Hospital East (JP)
• Osaka International Cancer Institute (JP)
• Nippon Medical School Hospital (JP)
• Hyogo Prefectural Cancer Center (JP)
• Japanese Foundation For Cancer Research (JP)
• Kindai University (JP)

Publication Details

Journal

Future Oncology

Published

2025-09-25

DOI

https://doi.org/10.1080/14796694.2025.2560225

Primary Topic

Lung Cancer Treatments and Mutations

Type

article

Field-Weighted Citation Impact

0.00